Stocktoria
PALISADE BIO, INC. PALI
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2006-12-20
PALISADE BIO, INC. statistics & valuation
Market cap$328.1M
P / B2.5×
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | — | — | -4356.7% | — | — |
| Net margin | — | — | -4100.0% | — | — |
| FCF margin | — | — | -3712.3% | — | — |
| Return on assets | -12.5% | -132.7% | -87.5% | -90.5% | -212.7% |
| Return on equity | -13.0% | -192.7% | -108.7% | -114.3% | -361.4% |
| Debt / equity | — | — | — | — | 0.01× |
| Current ratio | 28.95 | 3.24 | 5.15 | 4.89 | 4.61 |
| Revenue growth | — | -100.0% | — | — | — |
Source: SEC EDGAR filings · CIK 0001357459 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.